1 unchanged sentence
Insider Trading Arrangements
−Removed: No officer or director, as defined in Rule 16a-1(f) under the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the fiscal quarter .
+Added: Th e following officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) adopted or terminated a “Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K, as follows :
+Added: On February 29, 2024 , Brendan P.
+Added: Teehan , Executive Vice President, Chief Operating Officer and Head of Commercial , adopted a Rule 10b5-1 trading arrangement providing for the sale of up to 20,000 shares of our common stock.
+Added: The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c).
+Added: The duration of the trading arrangement is from May 29, 2024 until May 29, 2025, or earlier if and when all transactions under the trading arrangement are completed.
+Added: On May 30, 2024 , Mark C.
+Added: Schneyer , Executive Vice President and Chief Financial Officer , adopted a Rule 10b5-1 trading arrangement providing for the sale of up to 31,884 shares of our common stock.
+Added: The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c).
+Added: The duration of the trading arrangement is from August 28, 2024 until July 31, 2025, or earlier if and when all transactions under the trading arrangement are completed.
Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q, filed August 6, 2015).
4 unchanged sentences
Forms of Nonstatutory Stock Option Grant Notice and Stock Option Agreement under Acadia Pharmaceuticals Inc.
−Removed: 2010 Equity Incentive Plan.
+Added: 2010 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed May 9, 2024).
Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under Acadia Pharmaceuticals Inc.
−Removed: 2010 Equity Incentive Plan.
+Added: 2010 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q, filed May 9, 2024).
Forms of Performance Stock Unit Grant Notice and Performance Stock Unit Award Agreement under Acadia Pharmaceuticals Inc.
−Removed: 2010 Equity Incentive Plan.
−Removed: Employment Offer Letter, dated January 12, 2024, between the Registrant and Jennifer Rhodes (incorporated by reference to Exhibit 10.13 to the Registrant’s Annual Report on Form 10-K, filed February 28, 2024).
+Added: 2010 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q, filed May 9, 2024).
+Added: Acadia Pharmaceuticals Inc.
+Added: 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to Registration Statement No.
+Added: Forms of Standard Stock Option Grant Notice and Stock Option Agreement under the Acadia Pharmaceuticals Inc.
+Added: 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.2 to Registration Statement No.
+Added: Forms of Standard Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Acadia Pharmaceuticals Inc.
+Added: 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to Registration Statement No.
+Added: Forms of Director Stock Option Grant Notice and Stock Option Agreement under the Acadia Pharmaceuticals Inc.
+Added: 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.4 to Registration Statement No.
+Added: Forms of Director Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Acadia Pharmaceuticals Inc.
+Added: 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.5 to Registration Statement No.
+Added: Employment Offer Letter, dated February 22, 2024, between the Registrant and Elizabeth H.
Certification of Stephen R.
8 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following financial statements from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed on May 8, 2024, formatted in iXBRL (Inline Extensible Business Reporting Language), are filed herewith:
+Added: The following financial statements from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed on August 6, 2024, formatted in iXBRL (Inline Extensible Business Reporting Language), are filed herewith:
(i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Income (Loss), (iv) Condensed Consolidated Statements of Cash Flows, (v) Condensed Consolidated Statements of Stockholders’ Equity and (vi) Notes to Condensed Consolidated Financial Statements.
5 unchanged sentences
Acadia Pharmaceuticals Inc.
+Added: August 6, 2024
Executive Vice President and Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.